Grant-in-Aid for General Scientific Research (B)
|Allocation Type||Single-year Grants |
Laboratory animal science
|Research Institution||Teikyo University |
KUHARA Takatoshi Teikyo U. Sch. Med., Assistant professor, 医学部, 講師 (70134616)
TAJIMA Tomoko Teikyo U. Sch. Med., Research associate, 医学部, 助手 (90173145)
ISHIGURO Toshikazu Teikyo U. Sch. Med., Research associate, 医学部, 助手 (30082275)
TAMURA Hiroshi Teikyo U. Sch. Med., Associate professor, 医学部, 助教授 (30101728)
MAEJIMA Kazuyoshi Keio U. Sch. Med., Professor, 医学部, 教授 (70051464)
ABE Yoshiaki Teikyo U. Sch. Med., Professor, 医学部, 教授 (20089296)
|Project Period (FY)
1987 – 1989
Completed (Fiscal Year 1989)
|Budget Amount *help
¥6,900,000 (Direct Cost: ¥6,900,000)
Fiscal Year 1989: ¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 1988: ¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1987: ¥2,800,000 (Direct Cost: ¥2,800,000)
|Keywords||Mycoplasma / Sendai virus / Monoclonal antibodies / Antiidiotype antibodies / センダイ・ウィルス / モノクローナル抗体 / 肺炎 / 免疫|
Results of the Project
1.Both humoral and cell-mediated immune responses were depressed in Mycoplasma Pulmonis ( M. pulmonis )-infected DBA/2 mice 2 to 6 weeks after infection.
2.Antibody responses to sheep red blood cells were augmented in M. pulmonis-infected athymic BALB/C nude( nu/nu ) mice 1 to 4 weeks after infection.
3.About 30 hybridoma clones which produce monoclonal antibodies to M. pulmonis were obtained.
4.Among the monoclonal antibodies to M. pulmonis, 2 monoclonal antibodies were found to have the ability to inhibit slightly the formation of lung lesions caused by M. pulmonis infection.
5.Sera obtained from M. pulmonis-infected mice were found to have the ability to inhibit significantly the formation of lung lesions caused by M. pulmonis infection.
6.About 15 hybridoma clones which produce monoclonal antibodies to Sendai virus ( HVJ were obtained. Among the monoclonal antibodies to Sendai virus, none of them were found to have the ability to protect animals from Sendai virus infection.
7.Many hybridomas which produce antibodies to streptococcal erythrogenic toxin were obtained, but the cloning of the hybridomas has not yet been performed.
Future Aspects of the Project
1.Monoclonal antibodies to various pathogenic agents in laboratory animals will be produced. Anti-idiotype antibodies (preferably monoclonal anti-idiotype antibodies) to those monoclonal antibodies will be produced and applied as vaccine.
2.Hybridoma clones which produce monoclonal antibodies to streptococcal erythrogenic toxin will be produced.